Načítá se...
Low‐dose IL‐2 induces CD56(bright )NK regulation of T cells via NKp44 and NKp46
Low‐dose interleukin (IL)‐2 has shown clinical benefits in patients with autoimmune and inflammatory diseases. Both regulatory T cells (T(regs)) and natural killer (NK) cells are increased in response to low‐dose IL‐2 immunotherapy. The role of regulatory T cells in autoimmune diseases has been exte...
Uloženo v:
| Vydáno v: | Clin Exp Immunol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7232012/ https://ncbi.nlm.nih.gov/pubmed/31989589 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13422 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|